Iv%25252525252525252525252520dexamethasone

# IV Dexamethasone ## Overview Dexamethasone is a potent, long-acting synthetic glucocorticoid with minimal mineralocorticoid activity. It provides profound anti-inflammatory and immunosuppressive effects. ## Primary Indications * Cerebral edema (associated with neoplasms or neurosurgery) * Severe allergic reactions/anaphylaxis (adjunctive therapy) * Bacterial meningitis (adjunctive to reduce CNS inflammation) * Refractory shock or COVID-19 (associated with respiratory failure) * Nausea and vomiting prophylaxis (chemotherapy-induced) ## Adult Dosing * **Cerebral edema:** Initial 10 mg IV, followed by 4 mg IV every 6 hours. * **COVID-19:** 6 mg IV once daily for up to 10 days. * **Anti-emetic (CINV):** 10–20 mg IV 30 minutes prior to chemotherapy. * **Bacterial Meningitis:** 10 mg IV every 6 hours for 4 days (should be administered 15–20 minutes prior to or concomitant with first antibiotic dose). * **Anaphylaxis/Severe inflammation:** 4–20 mg IV as a single dose; may repeat if necessary. ## Pediatric Dosing * **Bacterial Meningitis:** 0.15 mg/kg IV every 6 hours for 4 days (initiate before or with first antibiotic). * **Cerebral edema:** 1–2 mg/kg loading dose, then 1–1.5 mg/kg/day divided every 4–6 hours. * **Anti-emetic:** 0.25–0.5 mg/kg (max 20 mg) as a single dose. * **Croup:** 0.6 mg/kg (max 10 mg) as a single dose. ## Dose Adjustments * **Hepatic impairment:** May require dose reduction or increased monitoring due to decreased clearance; however, no standardized adjustments exist. * **Geriatric:** Use lowest effective dose due to increased risk of hyperglycemia and psychiatric side effects. ## Contraindications * Hypersensitivity to the drug or components. * Systemic fungal infections. * Administration of live or live-attenuated vaccines. * Cerebral malaria (clinical studies showed no benefit/potential harm). ## Adverse Effects * **Endocrine:** Hyperglycemia/diabetes mellitus development, adrenal suppression. * **GI:** Peptic ulceration, GI bleeding. * **CNS:** Insomnia, mood swings, psychosis, anxiety. * **Electrolytes:** Hypokalemia, fluid retention/edema. * **Dermatologic:** Impaired wound healing. ## Key Drug Interactions * **CYP3A4 Inducers (e.g., phenytoin, carbamazepine, rifampin):** May reduce dexamethasone concentrations. * **CYP3A4 Inhibitors (e.g., ritonavir, ketoconazole):** May increase dexamethasone concentration. * **NSAIDs:** Increased risk of GI ulceration/bleeding. * **Warfarin:** Variable effect on INR; monitor closely. * **Antidiabetic agents:** Dexamethasone antagonizes hypoglycemic effects. ## Monitoring * Serum glucose (especially in diabetics). * Electrolytes (Potassium). * Blood pressure. * Signs of GI bleeding or infection. * Neurological status (in cerebral edema). ## Clinical Pearls * **Tapering:** Long-term administration requires a gradual taper to avoid acute adrenal insufficiency; short courses (e.g., < 5–7 days) typically do not require tapering. * **Administration:** IV dose is equivalent to oral dose (high bioavailability). * **Timing:** Administer in the morning when possible to minimize insomnia. * **Protocol Dependency:** Dosing for specific oncology regimens or sepsis protocols often deviates based on institutional guidelines; always check local clinical pathways. *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by institution and patient-specific factors. Always consult current institutional protocols and the most recent prescribing information (package insert) before administering medication.